Fujian Haixi Pharmaceuticals (2637 HK): Synthetic Expert Call Transcript (08 Oct 2026)
Imminent Pre-IPO Lockup Expiration: On October 20, 2026, the lockup on Fujian Haixi’s pre-IPO investors is set to expire, releasing half of the...
87 Views
Aequitas: Fujian Haixi Pharma IPO Lockup - Half of the Company’s Shares Worth US$800m to Be Released
Fujian Haixi Pharmaceuticals (2637 HK) was listed in Oct 2025, when it raised around US$126m in its HK IPO. The lockup on its pre-IPO investors is...
90 Views
Primer: Fujian Haixi Pharmaceuticals (2637 HK) - Aug 2026
Fujian Haixi Pharmaceuticals is a high-growth, commercial-stage company successfully leveraging stable revenue from its generic drug portfolio...
86 Views
APAC Healthcare Weekly (Sept 6) – Simcere, Hutchmed, Akeso, Daiichi Sankyo, Alteogen, Pharmaessentia
Simcere and Hutchmend inked outlicensing deals with Roche and GSK, respectively. Akeso’s ivonescimab extends lives vs Keytruda. Alteogen inked...
103 Views
Aequitas ECM Weekly (12 October 2026)-Wuxi Bio, CIG, CKD, Infroneer, JIO, ESWIN, Tinci, Transsion
Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
100 Views